ES2605946T3 - Imidazopiridazinas sustituidas - Google Patents

Imidazopiridazinas sustituidas Download PDF

Info

Publication number
ES2605946T3
ES2605946T3 ES13710986.4T ES13710986T ES2605946T3 ES 2605946 T3 ES2605946 T3 ES 2605946T3 ES 13710986 T ES13710986 T ES 13710986T ES 2605946 T3 ES2605946 T3 ES 2605946T3
Authority
ES
Spain
Prior art keywords
alkyl
group
halo
alkoxy
represent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13710986.4T
Other languages
English (en)
Inventor
Marcus Koppitz
Ulrich Klar
Antje Margret Wengner
Roland Neuhaus
Gerhard Siemeister
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Bayer Intellectual Property GmbH
Original Assignee
Bayer Pharma AG
Bayer Intellectual Property GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG, Bayer Intellectual Property GmbH filed Critical Bayer Pharma AG
Application granted granted Critical
Publication of ES2605946T3 publication Critical patent/ES2605946T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un compuesto de fórmula general I:**Fórmula** en la que: A representa**Fórmula** en la que * indica el punto de unión de dicho grupo con el resto de la molécula; R2 representa un grupo metilo, etilo o ciclopropilo; en el que dicho grupo metilo o etilo está opcionalmente sustituido, en forma idéntica o diferente, con 1, 2, 3 o 4 grupos seleccionados entre: halógeno, -OH, -CN, alcoxi C1-C3-; en el que dicho grupo ciclopropilo está opcionalmente sustituido, en forma idéntica o diferente, con 1, 2, 3 o 4 grupos seleccionados entre: halógeno, -OH, -CN, alquil C1-C3-, alcoxi C1-C3-, HO-alquil C1-C3-, halo-alquil C1-C3-; R3 representa -C (R3a)(R3b)(R3c); R3a, R3b representan, independientemente cada uno del otro, un átomo de hidrógeno o un átomo de halógeno o un grupo hidroxi, alquil C1-C3-, HO-alquil C1-C3-, alquenil C2-C4-, halo-alquil C1-C3-, alcoxi C1-C3- o halo-alcoxi C1-C3-, con la condición de que R3a y R3b no representan ambos un átomo de hidrógeno y R3a y R3b no representan ambos un grupo hidroxi; o R3a, R3b juntos representan >=O o >=C(R3d)(R3e); o R3a, R3b junto con el átomo de carbono al que se unen, forman un anillo ciclopropilo o ciclobutilo; en el que dicho anillo ciclopropilo o ciclobutilo está opcionalmente sustituido, en forma idéntica o diferente, con 1 o 2 grupos R3d; o R3 representa**Fórmula** en la que * indica el punto de unión de dicho grupo con el resto de la molécula; R3c representa un grupo fenilo; en el que dicho grupo fenilo está sustituido, en forma idéntica o diferente, con 1, 2, 3 o 4 grupos R7; R3d, R3e representan, en forma independiente entre sí, un átomo de hidrógeno o un grupo alquil C1-C3-; R4 representa un átomo de hidrógeno, un átomo de halógeno, o un grupo -CN, alquil C1-C3-, alcoxi C1-C3-, halo-alquil C1-C3- o halo-alcoxi C1-C3-; R5 representa un grupo alquil C1-C6-, -(CH2)m-(heterocicloalquilo de 3 a 7 miembros), alcoxi C1-C6-alquil C1-C6- o halo-alquil C1-C6- ; en el que dicho grupo -(CH2)m-(heterocicloalquilo de 3 a 7 miembros) está opcionalmente sustituido, en forma idéntica o diferente, con 1, 2 o 3 grupos R8 ; R6, R6a, R6b representan, independientemente cada uno del otro, un átomo de hidrógeno o un grupo alquil C1-C6-; R7 representa un átomo de halógeno, o un grupo hidroxi-, -CN, alcoxi C1-C6-, alquil C1-C6-, halo-alquil C1-C6-, R6a(R6b)Nalquil C1-C6-, HO-alquil C1-C6-, alcoxi C1-C6-alquil C1-C6-, halo-alcoxi C1-C6-alquil C1-C6-; R8 representa un átomo de halógeno, o un grupo -CN, hidroxi-, alquil C1-C6-, halo-alquil C1-C6-, HO-alquil C1-C6-, alcoxi C1-C6- o halo-alcoxi C1-C6-; m es un número entero de 0, 1 o 2 ; n es un número entero de 0, 1 o 2 ; o un estereoisómero, un tautómero, un N-óxido, un hidrato, un solvato o una sal farmacéuticamente aceptable del mismo o una mezcla de los mismos.
ES13710986.4T 2012-03-14 2013-03-11 Imidazopiridazinas sustituidas Active ES2605946T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12159455 2012-03-14
EP12159455 2012-03-14
EP13154139 2013-02-06
EP13154139 2013-02-06
PCT/EP2013/054841 WO2013135612A1 (en) 2012-03-14 2013-03-11 Substituted imidazopyridazines

Publications (1)

Publication Number Publication Date
ES2605946T3 true ES2605946T3 (es) 2017-03-17

Family

ID=47913379

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13710986.4T Active ES2605946T3 (es) 2012-03-14 2013-03-11 Imidazopiridazinas sustituidas

Country Status (10)

Country Link
US (1) US9512126B2 (es)
EP (1) EP2825540B1 (es)
JP (1) JP6166289B2 (es)
CN (1) CN104284896B (es)
AR (1) AR090323A1 (es)
CA (1) CA2867061A1 (es)
ES (1) ES2605946T3 (es)
HK (1) HK1206022A1 (es)
UY (1) UY34677A (es)
WO (1) WO2013135612A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9512126B2 (en) 2012-03-14 2016-12-06 Bayer Intellectual Property Gmbh Substituted imidazopyridazines
MX2015017119A (es) 2013-06-11 2016-04-06 Bayer Pharma AG Derivados de prodroga de triazolpiridinas sustituidas.
MA38657A1 (fr) * 2013-06-13 2018-05-31 Bayer Pharma AG Combinaison d'un dérivé d'imidazopyridazine et d'un agent mitotique pour le traitement du cancer
EP3283642B1 (en) 2015-04-17 2023-10-11 Netherlands Translational Research Center Holding B.V. Prognostic biomarkers for ttk inhibitor chemotherapy
IL288541B (en) 2015-07-07 2022-08-01 Janssen Vaccines Prevention B V vaccine against rsv
GB201907616D0 (en) * 2019-05-29 2019-07-10 Galapagos Nv Novel compounds and pharmaceutical compositons thereof for the treatment of diseases

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
HUP9903965A3 (en) 1996-08-28 2002-02-28 Pfizer Substituted 6,5-hetero-bicyclic derivatives
DK0991628T3 (da) 1997-05-28 2005-05-17 Aventis Pharma Inc Quinolin- og quinoxalinforbindelser, der inhiberer blodpladeafledt vækstfaktor og/eller p561ck-tyrosin-kinaser
US6514989B1 (en) 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
JP2004346016A (ja) 2003-05-22 2004-12-09 Otsuka Chemical Co Ltd トリフルオロメチルキノキサリン化合物、その製造方法、及び有害生物防除剤
WO2005030121A2 (en) 2003-06-30 2005-04-07 Hif Bio, Inc. Compounds, compositions and methods
EP1799680A2 (en) 2004-10-07 2007-06-27 Warner-Lambert Company LLC Triazolopyridine derivatives as antibacterial agents
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
WO2007065010A2 (en) 2005-12-02 2007-06-07 Hif Bio, Inc. Anti-angiogenesis compounds
KR20090026288A (ko) 2006-05-31 2009-03-12 갈라파고스 엔.브이. 퇴행성 및 염증성 질환의 치료에 유용한 트리아졸로피라진 화합물
AU2007284562B2 (en) 2006-08-16 2013-05-02 Exelixis, Inc. Using PI3K and MEK modulators in treatments of cancer
CN103641829A (zh) 2006-08-30 2014-03-19 塞尔佐姆有限公司 作为激酶抑制剂的三唑衍生物
WO2008133192A1 (ja) * 2007-04-19 2008-11-06 Takeda Pharmaceutical Company Limited 縮合イミダゾール化合物およびその用途
US7592342B2 (en) 2007-05-10 2009-09-22 Smithkline Beecham Corporation Quinoxaline derivatives as PI3 kinase inhibitors
KR20100049073A (ko) 2007-07-18 2010-05-11 노파르티스 아게 비시클릭 헤테로아릴 화합물 및 키나제 억제제로서의 그의 용도
JP2010535804A (ja) 2007-08-09 2010-11-25 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Pi3キナーゼ阻害薬としてのキノキサリン誘導体
MX2010002115A (es) 2007-08-23 2010-06-01 Aztrazeneca Ab 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos .proliferativos.
US8263595B2 (en) 2007-08-31 2012-09-11 Merck Serono Sa Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
CA2706578A1 (en) 2007-11-27 2009-06-04 Cellzome Limited Amino triazoles as pi3k inhibitors
WO2009155121A2 (en) 2008-05-30 2009-12-23 Amgen Inc. Inhibitors of pi3 kinase
TWI491610B (zh) 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
WO2010092015A1 (en) 2009-02-10 2010-08-19 Cellzome Limited Urea triazololo [1, 5-a] pyridine derivatives as pi3k inhibitors
NZ594508A (en) 2009-02-13 2013-12-20 Fovea Pharmaceuticals [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors
US8729082B2 (en) 2009-04-29 2014-05-20 Bayer Intellectual Property Gmbh Substituted imidazoquinoxalines
TW201107329A (en) * 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
EP2473498A1 (en) 2009-09-04 2012-07-11 Bayer Pharma Aktiengesellschaft Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
EP2343294A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
EP2343295A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
JP5824464B2 (ja) 2010-01-15 2015-11-25 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド γセクレターゼ調節物質としての新規置換トリアゾール誘導体
US20110190269A1 (en) 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
CA2801031A1 (en) 2010-06-01 2011-12-08 Bayer Intellectual Property Gmbh Substituted imidazopyrazines
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
ES2556458T3 (es) 2010-12-17 2016-01-18 Bayer Intellectual Property Gmbh 6-Imidazopirazinas sustituidas para uso como inhibidores de Mps-1 y TKK en el tratamiento de trastornos hiperproliferativos
ES2530802T3 (es) 2010-12-17 2015-03-06 Bayer Ip Gmbh Imidazopirazinas 6-tiosustituidas para uso como inhibidores de MPS-1 y TKK en el tratamiento de trastornos hiperproliferativos
HUE025496T2 (en) 2011-04-21 2016-04-28 Bayer Ip Gmbh Triazolopyridine derivatives
EP2734205B1 (en) * 2011-07-21 2018-03-21 Tolero Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors
US9512126B2 (en) 2012-03-14 2016-12-06 Bayer Intellectual Property Gmbh Substituted imidazopyridazines

Also Published As

Publication number Publication date
EP2825540A1 (en) 2015-01-21
AR090323A1 (es) 2014-11-05
US9512126B2 (en) 2016-12-06
JP2015513559A (ja) 2015-05-14
CA2867061A1 (en) 2013-09-19
US20150104526A1 (en) 2015-04-16
WO2013135612A1 (en) 2013-09-19
JP6166289B2 (ja) 2017-07-19
UY34677A (es) 2013-10-31
HK1206022A1 (zh) 2015-12-31
EP2825540B1 (en) 2016-09-14
CN104284896B (zh) 2016-06-01
CN104284896A (zh) 2015-01-14

Similar Documents

Publication Publication Date Title
ES2605946T3 (es) Imidazopiridazinas sustituidas
CR20170118A (es) Derivados espirodiamina como inhibidores de la aldosterona sintasa
AR105845A1 (es) Compuestos de heteroarilo bicíclicos fusionados como moduladores de la función irak4
AR089143A1 (es) Triazolopiridinas sustituidas con actividad inhibidora de ttk
AR091193A1 (es) HETEROCICLOS DE 5 MIEMBROS QUE CONTIENEN NITROGENO SUSTITUIDO POR CARBOXAMIDA O SULFONAMIDA COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUERFANO RORg
ES2770058T3 (es) Compuestos y composiciones destinados a modular las actividades de quinasa de EGFR mutante
AR101189A1 (es) Heterociclos nitrogenados antiproliferativos y sus métodos de uso
CL2016002348A1 (es) Agonistas del receptor muscarínico
PE20180483A1 (es) Oxiesteroles y metodos de uso de los mismos
EA201791873A1 (ru) Полиморф ингибиторов syk
MX2016011992A (es) Derivados de piperidina-diona.
AR103833A1 (es) Compuestos bicíclicos de sulfonamida cetona
MA40171A (fr) Dérivés d'azamophinan et leur utilisation
AR094300A1 (es) Derivados de quinolonas
AR085327A1 (es) Inhibidores del virus de la hepatitis c
MA39956A (fr) Analogues du benzomorphane et leur utilisation
CU20170007A7 (es) Compuestos de imidazopiridazina
AR094762A1 (es) Compuestos de hexahidropirano[3,4-d][1,3]tiazin-2-amina sustituida con heteroarilo
PE20160885A1 (es) Derivados de purina 2,6 sustituidos en el tratamiento de transtornos proliferativos
PE20160201A1 (es) Bencil-1h-pirazol[3,4-b]piridinas y su uso
CL2019000662A1 (es) Inhibidores de dopamina–b–hidroxilasa.
AR111494A1 (es) Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer
AR099047A1 (es) Derivados etinilo
AR095040A1 (es) Antagonistas de h3 que contienen un núcleo estructural de fenoxipiperidina
MX2017011978A (es) Analogos deuterados de etifoxina, sus derivados y usos de estos.